Depression (November)

Date of Issue: 11/01/2013 | Volume: 11 | Number: 11

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue


Fire in the Mind: The Depression-Inflammation Connection

Topics: Depressive Disorder

We have all bumped up against the limits of the current model of antidepressant treatments for depression: the patient who comes in with a laundry list of failed medication trials, or a number of other complaints depicting a portrait of malaise—aches, pains, anhedonia, fatigue, brain fog, digestive woes—that don’t really respond to currently available agents. What if shifting our thinking about underlying causes might hold the answer to treatment of these individuals?

Read More

Clinical Trials: Show Us the Data

Topics: Laboratory Testing in Psychiatry | Pharmaceutical Industry

Too often our literature presents an oversimplified picture driven by some agenda, usually commercial. We prescribers, or, more accurately, “research consumers,” need a more complete and accurate description of what’s actually observed in clinical trials.

Read More

Does Brintellix Bring Anything New?

Topics: Antidepressants | Depressive Disorder

After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?

Read More
Research Update

Metformin for Weight Loss in Schizophrenia

Topics: Research Updates

Obesity and metabolic impairments are widespread in both psychiatric and non-psychiatric populations. To make matters worse, weight gain, hyperlipidemia, and diabetes are common side effects of the pharmaceuticals we use to treat psychiatric illness.

Read More
Expert Q&A

Ketamine for Depression

Topics: Depressive Disorder | Free Articles

Can a single infusion of ketamine treat depression? Dr Sanjay Mathew explores the buzz around this treatment.

Read More